Cardinal Health, Inc. (NYSE:CAH – Get Free Report) CEO Jason Hollar sold 44,529 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total transaction of $10,516,859.22. Following the transaction, the chief executive officer owned 190,603 shares of the company’s stock, valued at $45,016,616.54. This trade represents a 18.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Cardinal Health Stock Down 2.5%
Cardinal Health stock opened at $228.95 on Friday. The company’s 50-day moving average price is $231.91 and its 200-day moving average price is $217.78. Cardinal Health, Inc. has a twelve month low of $145.87 and a twelve month high of $258.30. The company has a market cap of $53.25 billion, a PE ratio of 31.67, a price-to-earnings-growth ratio of 1.26 and a beta of 0.49.
Cardinal Health (NYSE:CAH – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The firm had revenue of $63.67 billion for the quarter, compared to analysts’ expectations of $65.15 billion. During the same period in the prior year, the company earned $2.08 EPS. The business’s revenue was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, sell-side analysts expect that Cardinal Health, Inc. will post 12.54 earnings per share for the current fiscal year.
Cardinal Health Dividend Announcement
Key Headlines Impacting Cardinal Health
Here are the key news stories impacting Cardinal Health this week:
- Positive Sentiment: Royal Bank of Canada initiated coverage of Cardinal Health with a “moderate buy” or outperform-equivalent rating. RBC cited the integration of higher-margin services as a potential driver of future earnings outperformance. RBC Capital Starts Cardinal Health at Outperform
- Positive Sentiment: A Zacks analysis identified CAH as a potentially attractive long-term value stock, while recent coverage has highlighted Cardinal Health’s precision-medicine operations and higher-margin services as sources of sustained growth. Why Cardinal Health Is a Top Value Stock for the Long-Term
- Neutral Sentiment: Brokerages continue to assign Cardinal Health a consensus “moderate buy” rating. The constructive view is tempered by valuation and questions about the sustainability of recent earnings gains.
- Negative Sentiment: Multiple executives and insiders sold shares around $235–$237. Chief Executive Officer Jason Hollar sold a combined 124,529 shares worth approximately $29.4 million, while CEO Deborah Weitzman sold about $1.7 million. Other insider sales included Chief Accounting Officer Mary Scherer and executives Michelle Greene, Jessica Mayer, and Stephen Mason. The transactions substantially reduced several executives’ holdings and may signal that insiders are taking profits after the stock’s strong rally. Cardinal Health Insider Sale Filing
- Negative Sentiment: Although Cardinal Health reported adjusted quarterly EPS of $2.91, well above the $2.42 consensus, an analysis noted that a significant portion of the earnings improvement came from a one-time tariff refund. That raises concerns about the durability of the earnings beat and may be contributing to the weaker stock performance. Cardinal Health Earnings Analysis
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. Investors Research Corp purchased a new stake in shares of Cardinal Health in the second quarter worth approximately $29,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Cardinal Health during the 4th quarter worth approximately $26,000. Allied Private Wealth LLC purchased a new position in Cardinal Health during the 2nd quarter valued at $30,000. Bank of Jackson Hole Trust bought a new position in Cardinal Health in the 4th quarter valued at $27,000. Finally, Indiana Trust & Investment Management Co bought a new position in Cardinal Health in the 1st quarter valued at $29,000. Institutional investors own 87.17% of the company’s stock.
Analysts Set New Price Targets
CAH has been the subject of a number of recent research reports. TD Cowen lifted their target price on Cardinal Health from $275.00 to $280.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Morgan Stanley raised their price target on Cardinal Health from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Bank of America lifted their price objective on shares of Cardinal Health from $240.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Mizuho boosted their price objective on shares of Cardinal Health from $240.00 to $250.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Finally, UBS Group increased their target price on shares of Cardinal Health from $274.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $266.56.
Get Our Latest Analysis on CAH
Cardinal Health Company Profile
Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.
The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.
Featured Stories
- Five stocks we like better than Cardinal Health
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.
